Pipeline Insight: Substance Dependence - Nicotine

Questions: Discounts, Updates etc.

Price: $7,600.00

Publication Date: 2007-11-14

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The high prevalence of nicotine dependence, strong uptake of Pfizer's Chantix (varenicline), and the launch of new innovative therapies will cause the nicotine dependence prescription drug market to grow to $4.6 billion across the seven major markets by 2016. Innovative therapies are set to offer patients a convenient dosing regimen and thereby carrying the potential for improved compliance.


Scope

  • Analysis of patient potential, unmet needs and clinical trial design in nicotine dependence
  • Overview of the current nicotine dependence market, covering both prescription and OTC products
  • Overview of drugs in late stage clinical development for nicotine dependence
  • Profiles of key compounds in development for use in nicotine dependence, with forecasts of drug revenues to 2016 and insight from key opinion leaders


    • Report Highlights
    Nicotine vaccines are the most prevalent drug class in the late-stage pipeline. This represents a move away from nicotine replacement and nicotine agonist therapies, which have historically dominated the market. Datamonitor predicts nicotine vaccine companies will be important players in the market by 2016, led by Novartis's NIC-002.

    Nicotine vaccines are designed to prevent nicotine from entering the brain and thus reduce the pleasurable effect of smoking. The utility of vaccines in nicotine dependence lies in the long-term protection they provide along with minimal patient compliance and carry the potential for prophylactic use.

    With two compounds in late-stage development for the treatment of nicotine dependence, it is evident that Sanofi-Aventis is keen to penetrate this market. Although possessing a similar mechanism of action to Chantix, Datamonitor believes that the drug's shorter treatment course than the market leader represents a strong competitive advantage.


    Reasons to Purchase

  • Understand unmet needs and opportunities in this market based on the comments of interviewed key opinion leaders.
  • Benchmark key late-stage nicotine dependence compounds against the current market leader.
  • Assess the seven major market total sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential

    • Table of Contents

    Other users found this report page using the following search terms: smoking addiction chantix nicotine dependence nicotine substance lead factors dianicline clinical nicvax potential will

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.